In the observed group of 104 NSCLC patients with ALK or ROS1 gene rearrangements treated with ALK or ROS1 inhibitors, we observed a median PFS of 19 months and a median OS of 58 months. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.